MedPath

The Comparison of anti-inflammatory versus supplement dose of selenium in mild Graves' orbitopathy

Phase 1
Conditions
Clinical activity scoreGraves&#39
Quality of lifeOverall eye examinationsDisease progression
Registration Number
TCTR20180228005
Lead Sponsor
Ratchadapiseksompotch Research fund
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending (Not yet recruiting)
Sex
All
Target Recruitment
87
Inclusion Criteria

-Mild thyroid eye disease group according to EUGOGO recommendation
-Age above 18 years old
-Normal thyroid hormone level (FT4, FT3) for at least 6 months
-Thyroid eye symptoms less than 24 months

Exclusion Criteria

-Allergic reaction to selenium
-History of selenium use
-Pregnant or breast-feeding
-Recent history of orbital and eyelid surgery of less than 6 months

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Graves clinical activity score 0,6 months EUGOGO Graves clinical activity scaling
Secondary Outcome Measures
NameTimeMethod
Graves' Quality of life 0,3,6 months Graves' Quality of life Questionaire
© Copyright 2025. All Rights Reserved by MedPath